Clinical Trials
37 trialsNCT07217171 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
Phase 1 Recruiting
NCT07623642 2026-06-03
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
GV20 Therapeutics
Phase 2 Not yet recruiting
NCT07621601 2026-06-02
A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Hansoh BioMedical R&D Company
Phase 3 Not yet recruiting
NCT07405151 2026-06-01
MK-3475-06F
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07284186 2026-05-29
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
Phase 1 Recruiting
NCT06010303 2026-05-28
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 2 Completed
NCT05319730 2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06535607 2026-05-26
eVOLVE-02
AstraZeneca
Phase 2 Recruiting
NCT07109726 2026-05-22
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Phase 1/2 Recruiting
NCT07602842 2026-05-22
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
InduPro, Inc.
Phase 1/2 Not yet recruiting
NCT04210115 2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04550260 2026-05-13
KUNLUN
AstraZeneca
Phase 3 Active not recruiting
NCT07085091 2026-05-12
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology Inc.
Phase 1 Recruiting
NCT04389632 2026-05-11
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT07554521 2026-05-11
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
BeOne Medicines
Phase 2 Recruiting
NCT05799274 2026-05-05
RAD301
Radiopharm Theranostics, Ltd
Phase 1 Recruiting
NCT07218003 2026-05-04
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Phase 1 Enrolling by invitation
NCT07554456 2026-04-28
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT07463573 2026-04-24
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05208762 2026-04-20
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT04543617 2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06304974 2026-04-17
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT03114319 2026-04-16
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT07229313 2026-04-16
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Phase 1 Recruiting
NCT06545331 2026-04-15
DELTA-101
Exelixis
Phase 1 Recruiting
NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT07090499 2026-04-07
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT06657144 2026-04-06
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Recruiting
NCT06504615 2026-04-03
METAGIO
Bristol-Myers Squibb
Active not recruiting
NCT07277413 2026-04-03
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT06780111 2026-03-31
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07503808 2026-03-31
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
Phase 1 Recruiting
NCT04785820 2026-03-27
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Hoffmann-La Roche
Phase 2 Completed
NCT07189871 2026-03-27
BetaBart
Radiopharm Theranostics, Ltd
Phase 1/2 Recruiting
NCT07481058 2026-03-20
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04140500 2026-03-18
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1/2 Active not recruiting